Day: March 29, 2023

Berkshire Grey Reports Fourth-Quarter and Full-Year 2022 Results

Written by Customer Service on March 29, 2023. Posted in Earnings Releases And Operating Results.

Revenue of $66 Million for Full Year 2022 Meets Full Year Outlook Company Achieves Positive Gross Margins in Q4 BEDFORD, Mass. , March 29, 2023 (GLOBE NEWSWIRE) — Berkshire Grey Inc. (Nasdaq: BGRY) (the “Company”), a leader in AI-enabled robotic solutions that automate supply chain processes, today announced results for its fourth quarter and year ended December 31, 2022. The Company:Executed 71 installations of Berkshire Grey’s advanced robotics solutions during 2022. Entered 2023 with backlog of approximately $100 million. Increased total orders since inception to $265 million. Achieved positive gross margin in the fourth quarter of 2022.“We had another strong quarter in terms of execution, and we continue to make significant progress improving our financial performance,” said Tom Wagner, Chief Executive Officer of the Company....

Avalo Reports 2022 Financial Results and Provides Business Updates

Written by Customer Service on March 29, 2023. Posted in Earnings Releases And Operating Results.

Completed enrollment of the Phase 2 PEAK Trial of AVTX-002 in non-eosinophilic asthma (NEA); topline data expected in the second quarter of 2023 Disclosed cash of approximately $13 million as of December 31, 2022, non-inclusive of the February 2023 public offering Increased cash position with closing of public offering of common stock and warrants for gross proceeds of $15 million on February 7, 2023WAYNE, Pa. and ROCKVILLE, Md., March 29, 2023 (GLOBE NEWSWIRE) — Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced business updates and year-end financial results for 2022. “We made significant strategic and operational progress over the past year, by executing our goals of streamlining the pipeline to the most promising assets/trials, implementing corresponding infrastructure cost reductions, executing operationally and extending...

Abeona Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update

Written by Customer Service on March 29, 2023. Posted in Earnings Releases And Operating Results.

Expects to submit BLA for EB-101 to FDA in late-2Q/early-3Q 2023 based on positive Phase 3 VIITAL™ study results announced in 4Q 2022 Advancing AAV-based gene therapy candidates toward IND studies in Stargardt Disease, X-linked Retinoschisis, and Autosomal Dominant Optic Atrophy Strengthened senior management team with executive appointments and promotions NEW YORK and CLEVELAND, March 29, 2023 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results for the full year of 2022 and provided an update on progress toward achieving key corporate objectives. The Company will host a conference call and webcast today, March 29, 2023, at 8:30 a.m. ET, to discuss its financial results and business update. “Since announcing positive topline results for the Phase 3 VIITAL study late last year, we...

Minim Reports Fourth Quarter and Full Year 2022 Financial Results

Written by Customer Service on March 29, 2023. Posted in Earnings Releases And Operating Results.

MANCHESTER, NH, March 29, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – Minim, Inc. (Nasdaq: MINM), the creator of innovative internet access products under the globally-recognized Motorola brand, today reported fourth quarter and full year financial results for the period ended December 31, 2022. Full Year 2022 Financial Highlights: ● Net revenue of $50.6 million, down 8.7% compared to $55.4 million in 2021. ● Gross margin of 23.6% compared to 34.1% in 2021. ● Net loss of ($15.5) million compared to a net loss of ($2.2) million in 2021. ● Improved working capital through a 25.0% reduction in inventories and a 77.2% reduction in accounts payable. Recent Business Highlights ● Executed a 20% cost reduction plan accelerate path to profitability ● Expanded e-commerce offering on OfficeDepot.com with launch of eight Motorola home...

Aspo Oyj – Managers’ Transactions – Matti-Mikael Koskinen

Written by Customer Service on March 29, 2023. Posted in Public Companies.

Aspo PlcManagers’ transactionsMarch 29, 2023, at 3 p.m. Aspo Oyj – Managers’ Transactions – Matti-Mikael Koskinen ____________________________________________ Person subject to the notification requirement Name: Matti-Mikael Koskinen Position: Other senior manager Issuer: Aspo Oyj LEI: 7437000TB0GHDHLPX677 Notification type: INITIAL NOTIFICATION Reference number: 28061/4/4 ____________________________________________ Transaction date: 2023-03-28 Outside a trading venue Instrument type: SHARE ISIN: FI0009008072 Nature of transaction: RECEIPT OF A SHARE-BASED INCENTIVE Transaction details (1): Volume: 9,000 Unit price: 0 EUR Aggregated transactions (1): Volume: 9,000 Volume weighted average price: 0 EURAspo Plc Arto MeitsaloCFO For further information, please contact:Arto Meitsalo, CFO, tel. +358 40 5511422, arto.meitsalo@aspo.com Distribution:Nasdaq...

Aspo Oyj – Managers’ Transactions – Arto Meitsalo

Written by Customer Service on March 29, 2023. Posted in Public Companies.

Aspo PlcManagers’ transactionsMarch 29, 2023, at 3 p.m. Aspo Oyj – Managers’ Transactions – Arto Meitsalo ____________________________________________ Person subject to the notification requirement Name: Arto Juhani Meitsalo Position: Chief Financial Officer Issuer: Aspo Oyj LEI: 7437000TB0GHDHLPX677 Notification type: INITIAL NOTIFICATION Reference number: 28057/4/4 ____________________________________________ Transaction date: 2023-03-28 Outside a trading venue Instrument type: SHARE ISIN: FI0009008072 Nature of transaction: RECEIPT OF A SHARE-BASED INCENTIVE Transaction details (1): Volume: 9,000 Unit price: 0 EUR Aggregated transactions (1): Volume: 9,000 Volume weighted average price: 0 EURAspo Plc Rolf JanssonCEO For further information, please contact:Rolf Jansson, CEO, tel. +358 400 600 264, rolf.jansson@aspo.com Distribution:Nasdaq...

Aspo Oyj – Managers’ Transactions – Toni Santalahti

Written by Customer Service on March 29, 2023. Posted in Public Companies.

Aspo PlcManagers’ transactionsMarch 29, 2023, at 3 p.m. Aspo Oyj – Managers’ Transactions – Toni Santalahti ____________________________________________ Person subject to the notification requirement Name: Toni Santalahti Position: Other senior manager Issuer: Aspo Oyj LEI: 7437000TB0GHDHLPX677 Notification type: INITIAL NOTIFICATION Reference number: 28073/5/4 ____________________________________________ Transaction date: 2023-03-28 Outside a trading venue Instrument type: SHARE ISIN: FI0009008072 Nature of transaction: RECEIPT OF A SHARE-BASED INCENTIVE Transaction details (1): Volume: 2,700 Unit price: 0 EUR Aggregated transactions (1): Volume: 2,700 Volume weighted average price: 0 EURAspo Plc Arto MeitsaloCFO For further information, please contact:Arto Meitsalo, CFO, tel. +358 40 551 1422, arto.meitsalo@aspo.com Distribution:Nasdaq...

Aspo Oyj – Managers’ Transactions – Bo Rolf Jansson

Written by Customer Service on March 29, 2023. Posted in Public Companies.

Aspo PlcManagers’ transactionsMarch 29, 2023, at 3 p.m. Aspo Oyj – Managers’ Transactions – Bo Rolf Jansson ____________________________________________ Person subject to the notification requirement Name: Bo Rolf Jansson Position: Chief Executive Officer Issuer: Aspo Oyj LEI: 7437000TB0GHDHLPX677 Notification type: INITIAL NOTIFICATION Reference number: 28055/5/4 ____________________________________________ Transaction date: 2023-03-28 Outside a trading venue Instrument type: SHARE ISIN: FI0009008072 Nature of transaction: RECEIPT OF A SHARE-BASED INCENTIVE Transaction details (1): Volume: 22,500 Unit price: 0 EUR Aggregated transactions (1): Volume: 22,500 Volume weighted average price: 0 EURAspo Plc Arto MeitsaloCFO For further information, please contact:Arto Meitsalo, CFO, tel. +358 40 551 1422, arto.meitsalo@aspo.com Distribution:Nasdaq...

ProQR Announces Initial Pipeline Targets and Highlights Axiomer® RNA Editing Platform Technology at R&D Event

Written by Customer Service on March 29, 2023. Posted in Public Companies.

Initial pipeline programs with liver delivery to address Cholestatic Diseases targeting NTCP and Cardiovascular Disease targeting B4GALT1; initiation of clinical trials anticipated in late 2024/early 2025 Axiomer activity demonstrated across multiple preclinical in vitro, organoid, and in vivo models; up to 50% editing observed in rodent and non-human primates Beyond correction, broad applicability of Axiomer demonstrated in preclinical models with ability to modulate proteins by altering function, changing post-translational modifications, and modifying protein interactions Company reports YE 2022 financials; cash runway extended into mid-2026 following Eli Lilly milestone related to partnership expansion Virtual R&D event today at 10:00 am EDT/1600 CETLEIDEN, Netherlands & CAMBRIDGE, Mass., March 29, 2023 (GLOBE NEWSWIRE)...

Aspo Oyj – Managers’ Transactions – Mikko Heikkilä

Written by Customer Service on March 29, 2023. Posted in Public Companies.

Aspo PlcManagers’ transactionsMarch 29, 2023, at 3 p.m.Aspo Oyj – Managers’ Transactions – Mikko Heikkilä ____________________________________________ Person subject to the notification requirement Name: Mikko Heikkilä Position: Other senior manager Issuer: Aspo Oyj LEI: 7437000TB0GHDHLPX677 Notification type: INITIAL NOTIFICATION Reference number: 28064/5/4 ____________________________________________ Transaction date: 2023-03-28 Outside a trading venue Instrument type: SHARE ISIN: FI0009008072 Nature of transaction: RECEIPT OF A SHARE-BASED INCENTIVE Transaction details (1): Volume: 3,600 Unit price: 0 EUR Aggregated transactions (1): Volume: 3,600 Volume weighted average price: 0 EURAspo Plc Arto MeitsaloCFO For further information, please contact:Arto Meitsalo, CFO, tel. +358 40 551 1422, arto.meitsalo@aspo.com Distribution:Nasdaq...

Day: March 29, 2023

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice